Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

Simplified 11C-UCB-J PET quantification evaluated in Alzheimer’s disease, epilepsy, and healthy individuals

Mika Naganawa, Jean-Dominique Gallezot, Sjoerd Finnema, David Matuskey, Ming-Kai Chen, Adam Mecca, Nabeel Nabulsi, Yiyun Huang, Kamil Detyniecki, Christopher van Dyck and Richard Carson
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 542;
Mika Naganawa
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Dominique Gallezot
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sjoerd Finnema
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Matuskey
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming-Kai Chen
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Mecca
2Department of Psychiatry Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nabeel Nabulsi
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yiyun Huang
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kamil Detyniecki
1Department of Neurology Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher van Dyck
2Department of Psychiatry Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Carson
3PET Center, Department of Radiology and Biomedical Imaging Yale University New Haven CT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

542

Objectives: Human PET studies with 11C-UCB-J, a synaptic vesicle protein 2A (SV2A) radiotracer, demonstrated high brain uptake and fast kinetics with excellent test-retest reproducibility (3-9%) for distribution volume (VT) estimation using the one-tissue compartment (1TC) model (Finnema et al, JCBFM, 2017). However, the 1TC model requires arterial blood sampling and a PET scan of 60-90 min. To simplify the scan protocol, we evaluated the tissue-to-plasma (TTP) and tissue-to-reference (TTR) ratio method for quantification against the gold standard distribution volume (VT) and binding potential (BPND) in Alzheimer’s disease (AD), epilepsy (EP), and healthy controls (HC).

Methods: All PET scans were acquired for 90 min on the HRRT scanner. 11C-UCB-J was administered as a bolus injection over 1 min. Arterial blood sampling and metabolite analysis were conducted to obtain the input function to compute 1TC model parameters. Static TTP and TTR values were calculated at 60-90 min after injection in scans of three datasets: A: 26 HC scans (20 regions of interest (ROIs), including neocortices, putamen, caudate, cerebellum, and hippocampus); B: 19 scans of HCs and ADs (HC: n = 9, AD: n = 10, hippocampus); and C: 5 scans of EPs (ipsilateral and contralateral hippocampus). Regional TTR and BPND values were determined using centrum semiovale (CS) as a reference region. For dataset A, % differences of TTP and TTR-1 were computed for comparison with VT and BPND, respectively. In the patient groups, additional analyses were performed to compare the disease-specific changes using modeling and TTR. For dataset B, between-group differences were compared using t-test. For dataset C, asymmetry indices were calculated as 100 x (ipsilateral - contralateral) / contralateral.

Results: In dataset A, regional TTP and TTR-1 correlated well with VT (R2=0.81, P < 0.0001) and BPND (R2=0.93, P < 0.0001), respectively. Since plasma and tissue were not at equilibrium, TTP overestimated VT (TTP = 1.64 × VT + 1.94), with similar % difference between TTP and VT among the examined regions (CS: 79 ± 19%; gray matter: 77 ± 20%). Because there was similar overestimation between the target and reference regions, TTR-1 was very similar to BPND (TTR-1 = 0.96 × BPND + 0.03) and the % difference between TTR-1 and BPND was very close to zero (-2% ± 7%). In dataset B, % differences of TTP and TTR-1 were similar to those of the dataset A (TTP: 75 ± 21%; TTR-1: 3 ± 9%). Hippocampus TTR-1 matched well with BPND (TTR-1 = 1.00 × BPND + 0.03, R2=0.98, P < 0.0001). TTR-1 in the AD group slightly underestimated BPND (TTR-1: 1.48 ± 0.29 for HC and 0.90 ± 0.60 for AD, 1TC BPND: 1.49 ± 0.34 for HC and 0.94 ± 0.60 for AD). The HC-AD group difference was significant using both BPND and TTR-1 (TTR-1: P = 0.028, 1TC BPND: P = 0.018). In dataset C, the % overestimation of TTP over VT was larger (92 ± 12%) than that of the dataset A, but the % difference between TTR-1 and BPND was equally small (0 ± 8%). Hippocampus TTR-1 matched well with BPND (TTR-1 = 1.18 × BPND - 0.26, R2=0.94, P < 0.0001). Asymmetry indices were -14 ± 29% with 1TC BPND and -17 ± 25% with TTR-1. Simulations based on the fitted parameters suggested that the overall excellent agreement between TTR-1 and BPND is time-dependent, i.e., TTR-1 would overestimate BPND by ~36% (TTR-1 = 1.36 × BPND + 0.36) at later times (~5 hours post-injection) once transient equilibrium is reached [2].

Conclusions: TTR-1 from 60-90 min matched extremely well with 1TC BPND in multiple subject groups (HCs, ADs, EPs), suggesting that a short scan after tracer injection may be sufficient for accurate quantification of 11C&#8209;UCB&#8209;J specific binding. Since the agreement between TTR-1 and 1TC BPND is expected to be time-dependent, careful validation of simplified methods should be performed in each patient cohort. Research Support: 1R01NS094253-01, 1R01AG052560-01A1 References: [1] Finnema et al, J Cereb Blood Flow Metab, 2017, epub. [2] Carson et al, J Cereb Blood Flow Metab, 13:24-42, 1993

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 59, Issue supplement 1
May 1, 2018
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Simplified 11C-UCB-J PET quantification evaluated in Alzheimer’s disease, epilepsy, and healthy individuals
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Simplified 11C-UCB-J PET quantification evaluated in Alzheimer’s disease, epilepsy, and healthy individuals
Mika Naganawa, Jean-Dominique Gallezot, Sjoerd Finnema, David Matuskey, Ming-Kai Chen, Adam Mecca, Nabeel Nabulsi, Yiyun Huang, Kamil Detyniecki, Christopher van Dyck, Richard Carson
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 542;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Simplified 11C-UCB-J PET quantification evaluated in Alzheimer’s disease, epilepsy, and healthy individuals
Mika Naganawa, Jean-Dominique Gallezot, Sjoerd Finnema, David Matuskey, Ming-Kai Chen, Adam Mecca, Nabeel Nabulsi, Yiyun Huang, Kamil Detyniecki, Christopher van Dyck, Richard Carson
Journal of Nuclear Medicine May 2018, 59 (supplement 1) 542;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

Probes for Neuroimaging I

  • Synthesis of [11C]NR2B-SMe for evaluation as a PET radioligand for NR2B subunits in NMDA receptors
  • Age and sex effects on synaptic density in healthy humans as assessed with SV2A PET
  • Preclinical evaluation of the first adenosine A1receptor agonist radioligand for positron emission tomography (PET) imaging
Show more Probes for Neuroimaging I

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire